Guselkumab improves quality of life in patients with moderate-to-severe psoriasis, Study says
According to recent research, it has been found out that guselkumab maintains high levels of clinical response and patient-reported outcome (PRO) improvement through 5 years in patients with moderate-to-severe psoriasis.
The study is published in the British Journal of Dermatology.
Psoriasis is a chronic disease requiring long-term therapy. Hence, K. Reich and colleagues from the Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany carried out the present study with the objective to evaluate physician- and patient-reported outcomes (PROs) through week 252 in VOYAGE 1 and VOYAGE 2.
A total of 1829 patients were randomized at baseline to receive guselkumab 100 mg every-8-weeks, placebo, or adalimumab; placebo patients crossed-over to guselkumab at week 16. Adalimumab patients crossed-over to guselkumab at week 52 in VOYAGE 1, and randomized-withdrawal/retreatment occurred at weeks 28-76 in VOYAGE 2; all patients then received open-label guselkumab through week 252.
Efficacy and HRQoL endpoints were analyzed through week 252. Safety was monitored through week 264.
The following results were observed-
a. The proportions of patients in the guselkumab group who achieved clinical responses at week 252 in VOYAGE 1 and VOYAGE 2, respectively, were: 84.1% and 82.0% (PASI90); 82.4% and 85.0% (IGA0/1); 52.7% and 53.0% (PASI100); and 54.7% and 55.5% (IGA0).
b. HRQoL endpoints were achieved as follows: 72.7% and 71.1% of patients (Dermatology Life Quality Index 0/1 or no effect on patient's life); 42.4% and 42.0% (Psoriasis Symptoms and Signs Diary [PSSD] symptom score=0); and 33.0% and 31.0% (PSSD sign score=0).
c. In VOYAGE 2 only, approximately 45% of patients achieved ≥5-point reduction in SF-36 Physical/Mental component scores and 80% reported no anxiety/depression (Hospital Anxiety and Depression scores <8).
d. Similar findings were reported for adalimumab crossovers.
e. These effects were maintained from week 52 in VOYAGE 1 and week 100 in VOYAGE 2.
f. No new safety signals were identified.
Therefore, the authors concluded that "Guselkumab maintains high levels of clinical response and PRO improvement through 5 years in patients with moderate-to-severe psoriasis."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.